Pharmacodynamic Profile and Prevalence of Bleeding Episode in East Asian Patients with Acute Coronary Syndromes Treated with Prasugrel Standard-Dose versus De-escalation Strategy: A Randomized A-MATCH Trial.

Abstract

Compared with Caucasian patients, East Asian patients have the unique risk-benefit trade-off and different responsiveness to antithrombotic regimens. The aim of this study was to compare pharmacodynamic profile in East Asian patients with acute coronary syndromes (ACSs) treated with prasugrel standard-dose versus a de-escalation strategy. Before discharge, ACS patients with age <75 years or weight ≥60 kg (n = 255) were randomly assigned to the standard-dose (10-mg group) or de-escalation strategy (5-mg group or platelet function test [PFT]-guided group). After 1 month, VerifyNow P2Y12 assay-based platelet reactivity (P2Y12 reaction unit [PRU]) and bleeding episodes were evaluated. Primary endpoint was the percentage of patients with the therapeutic window (85 ≤ PRU ≤ 208). The 250 patients completed 1-month treatment. The percentage of patients within the therapeutic window was significantly lower in the 10-mg group (n = 85) compared with the 5-mg (n = 83) and PFT-guided groups (n = 82) (35.3 vs. 67.5 vs. 65.9%) (odds ratio [OR]: 3.80 and 3.54; 95% confidence interval [CI]: 2.01-7.21 and 1.87-6.69, respectively). Compared with the 10-mg group, the bleeding rate was tended to be lower with de-escalation strategies (35.3 vs. 24.1% vs. 23.2%) (hazard ratio [HR]: 0.58 and 0.55; 95% CI: 0.30-1.14 and 0.28-1.09, respectively). "PRU < 127" was the optimal cut-off for predicting 1-month bleeding events (area under the curve: 0.616; 95% CI: 0.543-0.689; p = 0.005), which criteria was significantly associated with early discontinuation of prasugrel treatment (HR: 2.00; 95% CI: 1.28-3.03; p = 0.001). In conclusion, compared with the standard-dose prasugrel, the prasugrel de-escalation strategy in East Asian patients presented with ACS showed a higher chance within the therapeutic window and a lower tendency toward bleeding episodes. REGISTRATION:  URL: https://clinicaltrials.gov. Unique identifier:NCT01951001.

• Authors: Young-Hoon Jeong, Ju-Hyeon Oh, Hyuck-Jun Yoon, Yongwhi Park, Jon Suh, Se-Whan Lee, Kyounghoon Lee, Jeong-Su Kim, Woo-Jung Chun, Yong-Hwan Park, Chang-Wook Nam, June-Hong Kim, Jong-Hwa Ahn, Seok-Jae Hwang, Jin-Yong Hwang, Udaya S Tantry, Paul A Gurbel, Eun-Seok Shin
• Journal: Thrombosis and haemostasis (Thromb Haemost) Vol. 121 Issue 10 Pg. 1376-1386 (10 2021) ISSN: 2567-689X [Electronic] Germany
• PMID: 33401330 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
• Copyright: Thieme. All rights reserved.

Chemical References

• Platelet Aggregation Inhibitors
• Purinergic P2Y Receptor Antagonists
• Prasugrel Hydrochloride

Topics

• Acute Coronary Syndrome (blood, diagnosis, drug therapy, ethnology)
• Aged
• Asian People
• Blood Platelets (drug effects, metabolism)
• Drug Monitoring
• Drug Tapering
• Female
• Hemorrhage (chemically induced, ethnology, prevention & control)
• Humans
• Male
• Middle Aged
• Platelet Aggregation Inhibitors (administration & dosage, adverse effects)
• Platelet Function Tests
• Prasugrel Hydrochloride (administration & dosage, adverse effects)
• Prevalence
• Prospective Studies
• Purinergic P2Y Receptor Antagonists (administration & dosage, adverse effects)
• Republic of Korea (epidemiology)
• Time Factors
• Treatment Outcome